Xtandi takes fight to prostate cancer rivals with survival dataPfizer and Astellas have new survival data for their prostate cancer drug Xtandi that could help it fend Share XXtandi takes fight to prostate cancer rivals with survival datahttps://pharmaphorum.com/news/xtandi-takes-fight-to-prostate-cancer-rivals-with-survival-data/
Xtandi catches up with Erleada in castration-sensitive prostate cancerPfizer and Astellas have bagged FDA approval for Xtandi in metastatic castration-sensitive prostate cancer (CSPC), cancelling out a Share XXtandi catches up with Erleada in castration-sensitive prostate cancerhttps://pharmaphorum.com/news/xtandi-catches-up-with-erleada-in-castration-sensitive-prostate-cancer/
EMA starts review of Xtandi in hormone-sensitive prostate cancerThe EU regulator has started the clock ticking on its review of Pfizer and Astellas’ prostate cancer drug Share XEMA starts review of Xtandi in hormone-sensitive prostate cancerhttps://pharmaphorum.com/news/ema-starts-review-of-xtandi-in-hormone-sensitive-prostate-cancer/
Prostate drug approved for use in non-metastatic casesThe US Food and Drug Administration has approved the drug Xtandi (enzalutamide) to treat men with advanced non-metastatic Share XProstate drug approved for use in non-metastatic caseshttps://pharmaphorum.com/news/prostate-drug-approved-for-use-in-non-metastatic-cases/
Pfizer confirms $14bn Medivation mergerDrug giant confirms press reports. Share XPfizer confirms $14bn Medivation mergerhttps://pharmaphorum.com/news/pfizer-confirms-14bn-medivation-merger/
